Published: Apr 8, 2010 9:00:00 AM
Media Contact: , firstname.lastname@example.org, 334-844-3447
Mark Davis, chemical and biomolecular engineering professor for the California Institute of Technology, will present the seminar "Nanoparticle Cancer Therapeutics: From Concept to Clinic" at 3:30 p.m. on Thursday, April 15, in 1103 Shelby Center. His seminar is part of the chemical engineering distinguished lecture series sponsored by Auburn University's Department of Chemical Engineering.
Davis will describe how nanoparticle medicines have the potential to change current cancer treatment methods. He will demonstrate his research on nanoparticle-based therapeutics containing small anti-cancer agents and siRNA and discuss recent clinical trials with the nanoparticle medicines to show how nanoparticle-based therapeutics can be effectively used.
Warren and Katharine Schlinger Professor of Chemical Engineering at the California Institute of Technology, Davis was the first engineer to win the National Science Foundation Alan T. Waterman Award. His research includes materials synthesis in zeolites and polymers to deliver a broad range of therapeutics. He also founded Insert Therapeutics Inc., a company that focused on the use of cyclodextrin-containing polymers for drug delivery applications, and Calando Pharmaceuticals, Inc. a company that created the first RNAi therapeutic for treating cancer.
Contributed by Cassity Hughes